QTTB insider transaction filings
Q32 Bio Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-21. Screen QTTB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-21 | 4/A | Lundberg Sven Ante — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Xu Diyong — Director, 10% owner | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | GRAYZEL DAVID S. — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Manke Isaac — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | TZIANABOS ARTHUR — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Iwicki Mark T — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Thistle Mary — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | LAPORTE KATHLEEN — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Violette Shelia M. — Chief Scientific Officer | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-07-20 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 | EDGAR |
| 2026-07-20 | 4 | Morrison Jodie Pope — CEO, Director | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Manke Isaac — Director | Option exercise (M): 53,521 @ $2.80 · Option exercise (M): 53,521 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Xu Diyong — Director, 10% owner | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Manke Isaac — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | TZIANABOS ARTHUR — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Iwicki Mark T — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Thistle Mary — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Xu Diyong — Director, 10% owner | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-06-01 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-03-20 | 4 | Violette Shelia M. — Chief Scientific Officer | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-03-20 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 | EDGAR |
| 2026-03-20 | 4 | Morrison Jodie Pope — CEO, Director | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-02-27 | 4 | Violette Shelia M. — Chief Scientific Officer | Sale (S): 2,815 @ $4.51 | EDGAR |
| 2026-02-27 | 4 | Kalowski Lee — CFO and President | Sale (S): 3,995 @ $4.51 | EDGAR |
| 2026-02-27 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 9,896 @ $4.51 | EDGAR |
| 2026-01-30 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 16,363 (derivative) @ $2.75 | EDGAR |
| 2026-01-30 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 20,363 (derivative) @ $2.75 | EDGAR |
| 2026-01-30 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 23,272 (derivative) @ $2.75 | EDGAR |
| 2025-12-04 | 4 | Kalowski Lee — CFO and President | Sale (S): 9,072 @ $3.46 | EDGAR |
| 2025-12-04 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 22,506 @ $3.46 | EDGAR |
| 2025-10-27 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Xu Diyong — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Manke Isaac — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | TZIANABOS ARTHUR — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Iwicki Mark T — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Thistle Mary — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Violette Shelia M. — Chief Scientific Officer | Sale (S): 2,990 @ $1.80 | EDGAR |
| 2025-08-28 | 4 | Kalowski Lee — CFO and President | Sale (S): 4,240 @ $1.80 | EDGAR |
| 2025-08-28 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 10,494 @ $1.80 | EDGAR |
| 2025-02-27 | 4 | Manke Isaac — Director | Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 · Disposition to issuer (D): 2,627 (derivative) @ $0 · Grant/award (A): 2,627 (derivative) @ $0 · Grant/award (A): 19,008 (derivative) @ $0 · Disposition to issuer (D): 19,008 (derivative) @ $0 · +1 more | EDGAR |
| 2025-02-27 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 · Disposition to issuer (D): 16,901 (derivative) @ $0 · Grant/award (A): 16,901 (derivative) @ $0 · Disposition to issuer (D): 161,323 (derivative) @ $0 · Grant/award (A): 161,323 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | TZIANABOS ARTHUR — Director | Disposition to issuer (D): 25,674 (derivative) @ $0 · Grant/award (A): 25,674 (derivative) @ $0 · Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | LAPORTE KATHLEEN — Director | Disposition to issuer (D): 5,431 (derivative) @ $0 · Grant/award (A): 5,431 (derivative) @ $0 · Disposition to issuer (D): 1,947 (derivative) @ $0 · Grant/award (A): 1,947 (derivative) @ $0 · Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Xu Diyong — Director | Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Campagna Jason — Chief Medical Officer | Grant/award (A): 37,500 @ $0 · Disposition to issuer (D): 87,738 (derivative) @ $0 · Grant/award (A): 87,738 (derivative) @ $0 · Disposition to issuer (D): 17,951 (derivative) @ $0 · Grant/award (A): 17,951 (derivative) @ $0 · Disposition to issuer (D): 70,687 (derivative) @ $0 · +1 more | EDGAR |
Recent 8-K events — Q32 Bio Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=QTTB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →